324
Appendix 2: EULAR Sjogren’s Syndrome Patient-Reported
Index ( ESSPRI )
Reprinted with permission from Seror R, Theander E, Brun JG, Ramos-Casals M,
Valim V, Dörner T, et al; EULAR Sjögren’s Task Force. Validation of EULAR pri-
mary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Ann Rheum Dis. 2015; 74: 859–866 from BMJ Publishing Group Ltd
References
- Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syn-
drome. Arch Intern Med. 2004;164:1275–84. - Brito-Zerón P, Ramos-Casals M, EULAR-SS task force group. Advances in the understanding
and treatment of systemic complications in Sjögren’s syndrome. Curr Opin Rheumatol.
2014;26:520–7. - Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol.
2014;6:247–55. - Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian
women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. Scand
J Rheumatol. 2004;33:39–43. - Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary
Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc.
2001;76:593–9. - Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjögren’s syndrome. Clin Exp
Rheumatol. 2008;26:S66–71. - Lopez-Jornet P, Camacho-Alonso F. Quality of life in patients with Sjogren’s syndrome and
sicca complex. J Oral Rehabil. 2008;35:875–81.
M.O. Hegazi et al.